Drug Trial Radar · NCT07239102
Firmonertinib in the Treatment of EGFR(+) NSCLC Patients With Central Nervous System Metastasis
Last checked: Nov 19, 2026Latest source record: Nov 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
300
Actual
Start
Jan 1, 2020
Primary completion
May 1, 2025
Study completion Oct 1, 2025
Sponsor
- Lead sponsor
- Beijing Tiantan HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 20, 2025
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a clinical retrospective study that will collect and analyze clinical data from all patients treated with fumeitinib mesylate in the Oncology Department of Tiantan Hospital between January 1, 2020 and May 31, 2025. The data collection will include general demographic characteristics (gender, age, family history, smoking history, etc.), clinicopathological features, NGS test reports, fumeitinib initiation time and dosage, concomitant medications, local treatments (surgery, radiotherapy, etc.), and baseline and follow-up imaging examinations related to efficacy and safety. The study will conduct: 1) clinical data analysis; and 2) exploration of resistance-related clinical characteristics and influencing factors.
Conditions
- EGFR Positive Non-small Cell Lung Cancer
- Central Nervous System Metastasis
- Leptomeningeal Metastasis
Interventions
FirmonertinibDrug
Firmonertinib any dose, oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- iPFSTime frame: From first dose until the event of interest, assessed between January 1, 2020 and May 30, 2025
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Li Xiaoyan
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.